Interesting facts
Interesting Facts About (2R,3S,5R)-5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol
This compound is notable for its role as a specific antiviral drug that has gained attention in recent years. Here are some intriguing points:
- Mechanism of Action: The compound functions by inhibiting viral replication, making it a potential therapeutic agent against various viral infections. The presence of the purine moiety enhances its ability to interact with viral enzymes.
- Structure Significance: The tetrahydrofuran ring structure contributes significantly to the compound's conformational flexibility and bioactivity, allowing it to effectively bind to the targeted biological molecules.
- Amino and Chloro Substituents: The amino and chloro groups add to the compound's complexity, influencing its reactivity and interaction with biological systems. These modifications can enhance selectivity towards specific viral targets.
- Research Implications: Ongoing research into this compound explores its potential to treat challenging conditions, including certain viral infections that have limited treatment options. This highlights the importance of chemical modification in drug design.
As one delves deeper into the asset of this compound, it becomes clear that the nuances of its chemical structure can significantly impact its pharmacological profile. In the words of a celebrated chemist, "Every atom in a molecule carries its own importance—its placement can lead to miraculous outcomes."
In summary, (2R,3S,5R)-5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol serves as a fascinating example of how intricate chemical configurations can lead to significant medical advancements.
Synonyms
Cladribine
2-Chloro-2'-deoxyadenosine
4291-63-8
Leustatin
2-CdA
Cladarabine
Litak
CldAdo
cladribina
mavenclad
Movectro
Mylinax
cladribinum
Leustat
2-chloro-deoxyadenosine
2ClAdo
Leustatin (TN)
RWJ-26251
Mavenclad (TN)
(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
NSC 105014
NSC-105014
BRN 0624220
CCRIS 9374
DTXSID8022828
HSDB 7564
CHEBI:567361
47M74X9YT5
Cladribine [USAN:USP:INN:BAN]
CLADRIBINE [MI]
CLADRIBINE [INN]
CLADRIBINE [JAN]
CLADRIBINE [HSDB]
CLADRIBINE [USAN]
CLADRIBINE [VANDF]
2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine
CLADRIBINE [MART.]
CLADRIBINE [USP-RS]
CLADRIBINE [WHO-DD]
(2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
CLADRIBINE [EMA EPAR]
DTXCID602828
CLADRIBINE [ORANGE BOOK]
CLADRIBINE [EP MONOGRAPH]
CLADRIBINE [USP IMPURITY]
CLADRIBINE [USP MONOGRAPH]
NSC-05014
NSC-105014-F
CLADRIBINE (MART.)
CLADRIBINE (USP-RS)
CLADRIBINE (EP MONOGRAPH)
CLADRIBINE (USP IMPURITY)
CLADRIBINE (USP MONOGRAPH)
Cladribine (USAN:USP:INN:BAN)
NSC105014
2'-Deoxy-2-chloroadenosine
Leustatine
2-Chloro-2-deoxyadenosine
Chlorodeoxyadenosine (2-CdA)
L01BB04
L04AA40
NSC105014-F
2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)-purine
2-Chlorodeoxyadenosine
Chlorodeoxyadenosine
ADENOSINE, 2-CHLORO-2'-DEOXY-
2-Chloro-2'-deoxy-beta-adenosine
Cladaribine
RWJ 26251
MLS000028377
2CdA
MFCD00153939
SMR000058553
(2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol
CL9
CAS-4291-63-8
2 Chlorodeoxyadenosine
SR-01000003063
UNII-47M74X9YT5
Adenosine, 2-chloro-2'-deoxy
2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine
NCGC00018167-03
S1199
Cladribine (Standard)
RWJ-26251-000
Opera_ID_1191
SCHEMBL3775
CHEMBL1619
Cladribine (JAN/USP/INN)
2-chloro-2'-deoxy-adenosine
cid_20279
MLS000028484
MLS000759397
MLS001077345
MLS001424194
Cladribine - Bio-X trade mark
GTPL4799
BDBM38920
Cladribine for peak identification
GLXC-05407
HMS2052K13
HMS2232C23
HMS3715F17
BCP02868
Tox21_110834
Tox21_300596
HY-13599R
AKOS015854898
AKOS015892544
AC-7591
BCP9000538
CCG-101116
CS-2057
DB00242
NC00366
NC06337
NCGC00022567-05
NCGC00022567-06
NCGC00022567-07
NCGC00022567-08
NCGC00164384-01
NCGC00254518-01
2-Chloro-2'-deoxyadenosine, antileukemic
AS-12366
BC164318
BP-25407
HY-13599
NS00005088
SW197746-4
D01370
AB00382963-17
AB00382963_19
Q414030
SR-01000003063-7
BRD-K93034159-001-25-8
SR-01000003063-10
Leustatin;9-(2-Deoxy-b-D-ribofuranosyl)-2-chloroadenine
Cladribine, European Pharmacopoeia (EP) Reference Standard
6-amino-2-chloro-9-(2-deoxy-beta-erythropentofuranosyl)purine
Cladribine, United States Pharmacopeia (USP) Reference Standard
6-amino-2-chloro-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine
(2R,3S,5R)-5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol
Cladribine for peak identification, European Pharmacopoeia (EP) Reference Standard
2-Chloro-2'-deoxyadenosine;Leustatin;9-(2-Deoxy-b-D-ribofuranosyl)-2-chloroadenine;2-Chloro-2'-deoxy-D-adenosine
24757-90-2
Solubility of (2R,3S,5R)-5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol
This complex compound displays interesting solubility characteristics that are essential for various applications in pharmaceutical science. The solubility of (2R,3S,5R)-5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol can be influenced by several factors:
However, it is also important to note that the actual solubility can be greatly influenced by:
From experimental studies, it is suggested that the compound exhibits moderate solubility in aqueous environments, making it a suitable candidate for research applications where solubility and stability are paramount. As one might summarize, "the solubility of a compound is a dance between its structural features and the environment it finds itself in."